Investigating Patient Satisfaction With Oral Anti-Cancer Treatment

KU Leuven90 enrolled

Overview

Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug. The main objective of this study is to evaluate the patient perspective in the treatment of advanced renal cell carcinoma with an oral anti-cancer drug. The following aspects will be investigated: * Intrinsic desire for information about treatment. * Patient satisfaction with treatment information. * Patient satisfaction with treatment. * Medication adherence. * Health-related quality of life. * The role of different health care professionals in the treatment of RCC with oral drugs This study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Clear Cell Renal Cell Carcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are 18 years or older, and who can be contacted by phone and/or e-mail are eligible for the study Exclusion Criteria: * Patients who are not able to understand Dutch or French will be excluded from the study

Locations (1)

Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie

Outcomes

Primary Outcomes

Medication adherence

At the first visit patients will receive their anti-cancer medication by the hospital in a pill box which electronically records openings cf. Medication Event Monitoring System (MEMS®, Aardex). The recorded information in this chip will be read in the hospital pharmacy each time the patient gets new capsules. This information is strictly confidential and can only be consulted by the research team at the KULeuven.

Time frame: one year

Secondary Outcomes

Extent of Information Desire (EID)

Extent of information desire will be assessed, using a standardised questionnaire, at the start of the treatment, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).

Time frame: one year

Patient Satisfaction with Cancer Treatment Education (Ps-CaTE)

Satisfaction with cancer treatment information will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).

Time frame: one year

Morisky Medication Adherence Scale (MMAS)

Medication adherence will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).

Time frame: one year

Cancer Therapy Satisfaction Questionnaire (CTSQ)

Satisfaction with cancer treatment will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).

Time frame: one year

Functional Assessment of Cancer Therapy - General (FACT-G)

Health-related quality of life will be assessed, using a standardised questionnaire, at the start of the treatment, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).

Time frame: one year

Functional Kidney Symptom Index (FKSI)

Health-related quality of life will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).

Time frame: one year

Satisfaction With Pharmacist (SwiP)

Satisfaction with the pharmacist will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).

Time frame: one year